Agilent Technologies

To provide trusted answers that advance quality of life by bringing trusted answers to our customers’ most critical questions.

Agilent Technologies SWOT Analysis

Updated: October 2, 2025 • 2025-Q4 Analysis

How to Use This Analysis

This analysis for Agilent Technologies was created using Alignment.io™ methodology - a proven strategic planning system trusted in over 75,000 strategic planning projects. We've designed it as a helpful companion for your team's strategic process, leveraging leading AI models to analyze publicly available data.

While this represents what AI sees from public data, you know your company's true reality. That's why we recommend using Alignment.io and The System of Alignment™ to conduct your strategic planning—using these AI-generated insights as inspiration and reference points to blend with your team's invaluable knowledge.

Powered by Leading AI Models

Anthropic

Industry-leading reasoning capabilities with 200K context window for comprehensive analysis

Google Gemini

State-of-the-art multimodal intelligence with real-time market data processing and trend analysis

OpenAI GPT

Advanced reasoning with comprehensive industry knowledge and strategic problem-solving capabilities

The Agilent SWOT analysis reveals a company at a strategic inflection point. Its formidable brand, installed base, and growing recurring revenue provide a stable foundation. However, cyclical market pressures, particularly in China, and intense competition from larger rivals expose vulnerabilities. The path forward is clear: Agilent must aggressively pivot towards the higher-growth biopharma and diagnostics arenas, transforming its business model to be more software and subscription-driven. The core challenge is execution—integrating its disparate software assets into a cohesive, intelligent lab platform. Success demands a relentless focus on these priorities to build a more resilient, faster-growing business and fully realize its mission of advancing the quality of life.

Thermo Fisher Scientific Danaher Waters Corporation PerkinElmer Bruker

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To provide trusted answers that advance quality of life by bringing trusted answers to our customers’ most critical questions.

Toggle Theme

Strengths

RECURRING: Revenue base is robust at ~59%, providing stability
BRAND: Reputation for quality & reliability drives customer loyalty
INSTALLED: Large base of instruments creates a consumables moat
SERVICES: CrossLab Group is a key differentiator and growth engine
DIVERSE: Broad portfolio serves pharma, environmental, and food

Weaknesses

CYCLICALITY: Instrument sales vulnerable to macro-economic downturns
CHINA: Recent market softness highlights significant geographic risk
INTEGRATION: Complex portfolio of software creates usability gaps
SCALE: Smaller than key competitors like Thermo Fisher and Danaher
INNOVATION: Pace of breakthrough hardware innovation has slowed

Opportunities

BIOPHARMA: High growth in cell/gene therapy and biologics markets
DIAGNOSTICS: Expand companion diagnostics (CDx) partnerships
SOFTWARE: Increase software attachment and subscription revenue
CROSS-SELL: Leverage installed base to sell more services/consumables
SUSTAINABILITY: Growing demand for PFAS and microplastics testing

Threats

COMPETITION: Intense pressure from larger, highly acquisitive rivals
MACRO: Cautious customer spending delays large capital expenditures
GEOPOLITICAL: US-China tensions could disrupt sales & supply chain
PRICING: Competitors using aggressive pricing to gain market share
SUPPLY-CHAIN: Lingering risks of component shortages and inflation

Key Priorities

DOMINATE: The high-growth biopharma and diagnostics market segments
ACCELERATE: The shift to a recurring revenue model via services/SaaS
INTEGRATE: Software platforms to create a seamless customer experience
MITIGATE: China market volatility via geographic diversification

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Agilent Technologies OKR

Updated: October 2, 2025 • 2025-Q4 Analysis

The Agilent OKR plan is a masterclass in strategic focus. It directly translates the critical priorities from the SWOT analysis into a clear, actionable, and ambitious roadmap. By prioritizing biopharma, recurring revenue, the intelligent lab, and global resilience, the plan confronts weaknesses head-on while seizing the most significant opportunities. The key results are specific, outcome-driven, and designed to create tangible value, moving beyond mere activity. This is not just a plan; it is a declaration of intent to build a more durable, innovative, and profitable Agilent, perfectly aligning the entire organization on the handful of objectives that will truly define its future success and market leadership.

Thermo Fisher Scientific Danaher Waters Corporation PerkinElmer Bruker

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To provide trusted answers that advance quality of life by bringing trusted answers to our customers’ most critical questions.

WIN BIOPHARMA & DX

Become the indispensable partner for life-changing therapies.

MARKET SHARE: Capture #1 or #2 market share position in three key cell analysis instrument categories
PARTNERSHIPS: Secure 5 new strategic companion diagnostic (CDx) development agreements with top pharma
LAUNCH: Successfully launch the next-gen nucleic acid solution, achieving 120% of its first-year revenue target
PIPELINE: Grow the qualified sales pipeline for our new advanced therapy manufacturing solutions by $100M

DRIVE RECURRING REVENUE

Build an unbreakable, predictable growth engine for Agilent.

CONTRACTS: Increase service contract attachment rate on new high-end instrument sales from 65% to 75%
CONSUMABLES: Grow share-of-wallet for consumables by 15% within our top 100 enterprise accounts
SUBSCRIPTION: Launch two new SaaS offerings and secure the first 1,000 seats by the end of the fiscal year
AI-SERVICE: Pilot our new AI-powered predictive maintenance service with 25 strategic customers

CREATE INTELLIGENT LAB

Deliver a seamless, predictive, and automated experience.

PLATFORM: Unify user authentication and data exchange between OpenLab and SLIMS for 50% of users
UPTIME: Reduce average instrument downtime for service contract customers by 20% via remote diagnostics
ADOPTION: Double the monthly active users of our cloud-based data analysis software platform
WORKFLOWS: Launch 10 new pre-validated, automated end-to-end workflows for key pharma applications

BUILD GLOBAL RESILIENCE

Fortify our business against geopolitical & market volatility.

GROWTH: Achieve >15% year-over-year revenue growth in India and Southeast Asia combined as a region
SUPPLY-CHAIN: Qualify a second source supplier for 80% of our top 50 critical single-source components
MANUFACTURING: Complete operational readiness of our new manufacturing facility in a diverse geography
TALENT: Establish a new R&D center of excellence outside of both the US and China to access new talent

METRICS

Recurring Revenue as % of Total Revenue: 62%
Adjusted Operating Margin: 26.5%
New Instrument Orders Growth: 5.0%

VALUES

Innovation and Contribution
Uncompromising Integrity
Trust, Respect, and Teamwork
Speed
Focus
Accountability

Build strategic OKRs that actually work. AI insights meet beautiful design for maximum impact.

Get Free OKR Template

Agilent Technologies Retrospective

AI-Powered Insights

Claude

Gemini

GPT

Agilent Technologies Q3 2024 Earnings Report and Investor Call Transcript
Agilent Technologies 2023 Form 10-K Annual Report
Agilent Corporate Website (agilent.com), including leadership and solutions pages
Competitor analysis of Thermo Fisher Scientific (TMO) and Danaher (DHR) investor materials
Industry reports on Life Science Tools and Diagnostics markets

Thermo Fisher Scientific Danaher Waters Corporation PerkinElmer Bruker

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To provide trusted answers that advance quality of life by bringing trusted answers to our customers’ most critical questions.

Toggle Theme

What Went Well

SERVICES: CrossLab Group showed resilience and strong growth
MARGINS: Effective cost management protected profitability
BIOPHARMA: Continued strength in key biopharma sub-segments
CASH-FLOW: Maintained healthy operating and free cash flow
CONSUMABLES: Stable demand for recurring revenue items

Not So Well

INSTRUMENTS: Weaker capital equipment sales due to cautious spending
CHINA: Significant market decline impacted overall revenue growth
GUIDANCE: Outlook reflects continued macroeconomic uncertainty
PHARMA: Slower growth in the overall pharma market vs. prior years
ACADEMIA: Government funding cycles impacted academic segment demand

Learnings

MODEL: The recurring revenue model is critical for stability
DIVERSIFY: Geographic concentration in China is a major risk factor
MARKETS: Biopharma remains the most durable long-term growth driver
AGILITY: Must be able to quickly adapt cost structure to demand
INVENTORY: Careful management is key in a fluctuating demand cycle

Action Items

SALES: Double down on selling service contracts and consumables
MARKETING: Launch targeted campaigns in resilient market segments
R&D: Continue investing in new products for biopharma and diagnostics
OPS: Diversify supply chain sourcing away from single-risk regions
FINANCE: Maintain disciplined capital allocation and cost controls

Run better retrospectives in minutes. Get insights that improve your team.

Get Free Retro Template

Organization	SWOT Analysis	OKR Plan	Top 6	Retrospective

Explore specialized team insights and strategies

Agilent Technologies Market

AI-Powered Insights

Claude

Gemini

GPT

Agilent Technologies Q3 2024 Earnings Report and Investor Call Transcript
Agilent Technologies 2023 Form 10-K Annual Report
Agilent Corporate Website (agilent.com), including leadership and solutions pages
Competitor analysis of Thermo Fisher Scientific (TMO) and Danaher (DHR) investor materials
Industry reports on Life Science Tools and Diagnostics markets

Founded: 1999 (spinoff from Hewlett-Packard)
Market Share: Leading positions in GC, LC; strong player in MS and cell analysis.
Customer Base: Pharma, biotech, academia, environmental, chemical, diagnostics labs.
Category:
Life Science Tools
SIC Code: 3826 Laboratory Analytical Instruments
NAICS Code: 334516 Analytical Laboratory Instrument Manufacturing
Location: Santa Clara, California
Zip Code: 95051 San Jose, California
Congressional District: CA-17 SAN JOSE
Employees: 18100

Competitors

Thermo Fisher Scientific View Analysis

Danaher View Analysis

Waters Corporation Request Analysis

PerkinElmer Request Analysis

Bruker View Analysis

Products & Services

No products or services data available

Distribution Channels

Agilent Technologies Business Model Analysis

AI-Powered Insights

Claude

Gemini

GPT

Agilent Technologies Q3 2024 Earnings Report and Investor Call Transcript
Agilent Technologies 2023 Form 10-K Annual Report
Agilent Corporate Website (agilent.com), including leadership and solutions pages
Competitor analysis of Thermo Fisher Scientific (TMO) and Danaher (DHR) investor materials
Industry reports on Life Science Tools and Diagnostics markets

Problem

Slow, manual, error-prone lab workflows
High cost of instrument downtime
Complex data analysis and interpretation
Regulatory compliance and data integrity

Solution

Reliable, high-precision instruments
Integrated lab management software
Proactive services and consumables
Application-specific workflow solutions

Key Metrics

Recurring revenue as % of total revenue
New instrument placements and orders
Service contract attachment rate
Adjusted operating profit margin

Unique

Trusted brand heritage from Hewlett-Packard
Global CrossLab service infrastructure
End-to-end solutions from sample to insight
Deep application expertise in key markets

Advantage

Vast installed base creates switching costs
Proprietary technology and patents
Direct customer relationships and trust
Economies of scale in manufacturing

Channels

Direct global sales and support teams
Online e-commerce and digital marketing
Value-added resellers and distributors
Scientific conferences and publications

Customer Segments

Pharmaceutical and biotechnology companies
Contract research/manufacturing orgs (CRO/CDMO)
Academic and government research labs
Environmental, food, and chemical testing labs
Hospitals and clinical diagnostic labs

Costs

R&D for new hardware and software
Global manufacturing and supply chain
Sales, marketing, and G&A expenses
Cost of service delivery and support

Agilent Technologies Product Market Fit Analysis

Updated: October 2, 2025

Agilent Technologies empowers labs to get trusted answers faster. Its integrated ecosystem of reliable instruments, intelligent software, and proactive services accelerates scientific discovery, maximizes lab productivity, and ensures data integrity for the world's leading pharma, biotech, and research organizations. This drives faster breakthroughs in medicine and ensures a safer world for everyone.

ACCELERATE DISCOVERY with reliable, high-performance instruments.

MAXIMIZE UPTIME with our global CrossLab services and support.

ENSURE COMPLIANCE with our industry-leading software solutions.

Before State

Siloed instruments, manual data analysis
Unpredictable instrument downtime, slow R&D
Fragmented lab workflows, compliance risks

After State

Integrated, automated lab ecosystems
Predictive maintenance, accelerated insights
Streamlined workflows, assured compliance

Negative Impacts

Delayed drug discovery, costly lab errors
Lost productivity, missed project deadlines
Higher operational costs, regulatory issues

Positive Outcomes

Faster time-to-market for new therapies
Increased lab productivity and asset uptime
Lower cost per sample, robust data integrity

Key Metrics

Customer Retention Rates

>90% for service contracts

Net Promoter Score (NPS)

~50-60 range, varies by product line

User Growth Rate

Tied to instrument placements & software adoption

Customer Feedback/Reviews

~200 reviews on G2 for software

Repeat Purchase Rates

High; consumables tied to instrument use

Requirements

Unified software platform across instruments
Smart, connected instruments with IoT/AI
Comprehensive service and support contracts

Why Agilent Technologies

Develop OpenLab & SLIMS software platforms
Embed diagnostics in all new instruments
Expand CrossLab service & consumable offerings

Agilent Technologies Competitive Advantage

Decades of instrument & application expertise
Global scale of service & support engineers
Massive proprietary dataset from installed base

Proof Points

Top 10 pharma companies are Agilent clients
Thousands of peer-reviewed scientific papers
FDA 21 CFR Part 11 compliance solutions

Agilent Technologies Market Positioning

AI-Powered Insights

Claude

Gemini

GPT

Agilent Technologies Q3 2024 Earnings Report and Investor Call Transcript
Agilent Technologies 2023 Form 10-K Annual Report
Agilent Corporate Website (agilent.com), including leadership and solutions pages
Competitor analysis of Thermo Fisher Scientific (TMO) and Danaher (DHR) investor materials
Industry reports on Life Science Tools and Diagnostics markets

Strategic pillars derived from our vision-focused SWOT analysis

Unify hardware, software, AI for seamless workflows

Dominate cell analysis & nucleic acid solutions

Lead in precision oncology & pathology tools

Drive growth in PFAS, renewables, microplastics

What You Do

Provide instruments, software, services for labs to get trusted answers.

Target Market

Scientists, researchers, and lab technicians in critical industries.

Differentiation

Reputation for instrument reliability and data quality.
Global service and support network (CrossLab Group).

Revenue Streams

Instrument sales (capital equipment)
Recurring consumables & services

Agilent Technologies Operations and Technology

AI-Powered Insights

Claude

Gemini

GPT

Agilent Technologies Q3 2024 Earnings Report and Investor Call Transcript
Agilent Technologies 2023 Form 10-K Annual Report
Agilent Corporate Website (agilent.com), including leadership and solutions pages
Competitor analysis of Thermo Fisher Scientific (TMO) and Danaher (DHR) investor materials
Industry reports on Life Science Tools and Diagnostics markets

Company Operations

Organizational Structure: Three core business groups: LSAG, DGG, ACG.
Supply Chain: Global manufacturing with sites in US, Germany, Singapore, China.
Tech Patents: Extensive portfolio in analytical instrumentation & diagnostics.
Website: https://www.agilent.com

Top Clients

Board Members

Agilent Technologies Competitive Forces

Threat of New Entry

LOW: High barriers to entry due to significant R&D investment, established brand reputation, global sales/service networks, and intellectual property protection.

Supplier Power

LOW-MODERATE: Agilent uses many suppliers for electronic components and raw materials, mitigating power of any single one, though some specialized components can be single-sourced.

Buyer Power

MODERATE: Large pharma customers have significant purchasing power, but high switching costs for validated instruments and workflows limit their ability to dictate terms.

Threat of Substitution

LOW: While workflows can be altered, there are few viable substitutes for the core analytical technologies (e.g., mass spectrometry) that Agilent provides for regulated testing.

Competitive Rivalry

HIGH: Intense rivalry with larger, well-funded competitors like Thermo Fisher and Danaher, who compete across price, innovation, and M&A.

Analysis of AI Strategy

Updated: October 2, 2025 • 2025-Q4 Analysis

The Agilent AI SWOT analysis underscores a monumental opportunity. Agilent is sitting on a data goldmine—decades of proprietary scientific instrument data—which is its ultimate unfair advantage. The strategic imperative is to refine this raw data into intelligent, high-value services. While facing internal challenges in legacy systems and a competitive talent market, the potential is immense. By focusing on AI-powered predictive maintenance and automated data insights, Agilent can transform its value proposition from selling instruments to selling guaranteed outcomes and accelerated discovery. This isn't just an initiative; it's the core of the company's future, enabling the creation of the truly 'Intelligent Lab' and cementing its market leadership for the next decade.

Thermo Fisher Scientific Danaher Waters Corporation PerkinElmer Bruker

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To provide trusted answers that advance quality of life by bringing trusted answers to our customers’ most critical questions.

Strengths

DATA: Massive, proprietary dataset from global instrument fleet
DOMAIN: Deep expertise in chemistry, biology, and lab workflows
ACCESS: Direct customer relationships for developing AI use cases
TRUST: Brand reputation for data integrity is a key asset for AI
CHANNEL: Global service team can deploy and support AI solutions

Weaknesses

LEGACY: Existing software architecture may not be AI-native
TALENT: Competition for top-tier AI/ML engineers is fierce
SILOS: Data may be fragmented across different business units/formats
CULTURE: Transitioning from hardware-first to AI-first mindset
MONETIZATION: Lacks clear models for pricing AI-driven features

Opportunities

PREDICTIVE: AI for instrument maintenance, maximizing customer uptime
INSIGHTS: AI-driven software to accelerate data analysis & discovery
AUTOMATION: AI to enable fully autonomous lab operations and workflows
DIAGNOSTICS: AI-powered image analysis for pathology and genomics
OPTIMIZATION: Use AI to improve internal manufacturing and supply chain

Threats

COMPETITORS: Rivals may develop or acquire superior AI capabilities
STARTUPS: Nimble AI-native startups could disrupt data analysis market
REGULATION: Evolving rules on AI in regulated GxP environments
SECURITY: AI models and data are high-value targets for cyberattacks
ACCURACY: Risk of reputational damage from flawed AI model outputs

Key Priorities

DATA: Unify and leverage proprietary instrument data for AI models
SERVICES: Launch AI-powered predictive maintenance and insight services
WORKFLOW: Embed AI features into OpenLab to automate data analysis
TALENT: Build a world-class AI/ML team through hiring and training

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Agilent Technologies Financial Performance

AI-Powered Insights

Claude

Gemini

GPT

Agilent Technologies Q3 2024 Earnings Report and Investor Call Transcript
Agilent Technologies 2023 Form 10-K Annual Report
Agilent Corporate Website (agilent.com), including leadership and solutions pages
Competitor analysis of Thermo Fisher Scientific (TMO) and Danaher (DHR) investor materials
Industry reports on Life Science Tools and Diagnostics markets

Profit: FY23 Net Income: $1.21 billion

Market Cap: $38.5 Billion (as of late 2024)

Stock Performance

Annual Report: Available on Agilent Investor Relations website

Debt: Long-term debt: ~$2.7 billion

ROI Impact: Focus on margin expansion and recurring revenue growth.

SWOT Index

Composite strategic assessment with 10-year outlook

/ 100

Market Leader

ICM Index

STRATEGIC ADVISOR ASSESSMENT

Agilent scores as a solid Market Leader. Its societal-level mission and strong strategic alignment (high Achievability) are assets. However, its growth is constrained by intense competition and market cyclicality, reflected in a balanced SWOT score. The OKRs are strong and category-shaping. Significant upside exists in its AI potential, given its massive data advantage. The final growth multiplier is tempered by a competitive TAM and high survival probability, indicating steady, defensible growth rather than explosive expansion.

SWOT Factors

Upside: 83.3 Risk: 80.0

OKR Impact

AI Leverage

Top 3 Strategic Levers

LEVER 1: Accelerate AI-powered predictive services on installed base

LEVER 2: Deepen penetration in cell/gene therapy & diagnostics

LEVER 3: Unify software platforms to create a sticky ecosystem

AI Disclosure

This report was created using the Alignment Method—our proprietary process for guiding AI to reveal how it interprets your business and industry. These insights are for informational purposes only and do not constitute financial, legal, tax, or investment advice.

Next Step

Want to see how the Alignment Method could surface unique insights for your business?

Request your custom report Contact our team

About Alignment LLC

Alignment LLC specializes in AI-powered business analysis. Through the Alignment Method, we combine advanced prompting, structured frameworks, and expert oversight to deliver actionable insights that help companies understand how AI sees their data and market position.